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Abstract
Background: Heart failure patients with implantable defibrillators (ICD) frequently visit the clinic for routine
device monitoring. Moreover, in the case of clinical events, such as ICD shocks or alert notifications for changes
in cardiac status or safety issues, they often visit the emergency department or the clinic for an unscheduled visit.
These planned and unplanned visits place a great burden on healthcare providers.
Internet-based remote device interrogation systems, which give physicians remote access to patients' data, are
being proposed in order to reduce routine and interim visits and to detect and notify alert conditions earlier.
Methods: The EVOLVO study is a prospective, randomized, parallel, unblinded, multicenter clinical trial designed
to compare remote ICD management with the current standard of care, in order to assess its ability to treat and
triage patients more effectively.
Two-hundred patients implanted with wireless-transmission-enabled ICD will be enrolled and randomized to
receive either the Medtronic CareLink® monitor for remote transmission or the conventional method of in-
person evaluations. The purpose of this manuscript is to describe the design of the trial. The results, which are
to be presented separately, will characterize healthcare utilizations as a result of ICD follow-up by means of
remote monitoring instead of conventional in-person evaluations.
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Hospitalization for heart failure (HF) is an increasingly
serious clinical issue and carries a heavy economic burden
[1]. Thus, new strategies to keep HF patients out of hospi-
tal are needed.
Based on positive outcomes from numerous randomized
controlled trials, the current guidelines for the manage-
ment of chronic HF [1] include the use of implantable
defibrillators (ICD) and defibrillators for resynchroniza-
tion therapy (CRT-D) as the standard care in selected
chronic HF patients.
The ability of implantable devices to continuously moni-
tor variables such as heart rate [2], the patient's daily activ-
ity [3], intra-thoracic impedance for the detection of fluid
accumulation [4], the occurrence of arrhythmias [5], and
the integrity of the system [6] may provide early warning
of changes in cardiac status or safety issues and allow early
management. A standard method of notifying alert condi-
tions in ICD uses a programmable feature that enables a
patient to be audibly alerted if any of the various parame-
ters exceeds the pre-defined range [7].
ICD patients visit the clinic for routine device monitoring
2–4 times per year [8,9]. However, many of these routine
device checks result in no programming or device changes
[10], and many patients suffer no clinically significant
events between visits. When these patients do have clini-
cal events, such as ICD shocks or device alert notifications,
they often visit the emergency department (ED) or clinic
for an unscheduled examination. These unplanned visits
place an even greater burden on healthcare providers.
Several major manufacturers of devices offer a technology
for remote ICD monitoring [11-13], with the purpose of
reducing unnecessary routine and interim visits, and
allowing physicians to remotely access patients' data.
Earlier detection and notification, combined with remote
management, may also have the effect of shifting health-
care visits from the ED to the clinic, thereby reducing costs
and the burden on the healthcare system. In addition,
remote monitoring with these enhanced features may
improve patients' quality of life by reducing anxiety
between follow-up visits.
This study has been designed to compare these remote
management capabilities with the current standard of




The Medtronic CareLink® system (Minneapolis, MN, USA)
includes a patient monitor plugged into a standard analog
telephone connection, and a lightweight wand to commu-
nicate with the implanted device [11]. Interrogation of the
device and transmission of the data occur when the
patient places the wand over the implanted device. More-
over, the system uses radiofrequency telemetry for auto-
matic wireless communication. This allows data
transmission without patient intervention and enables
automatic transmission at scheduled intervals as well as
alert-based downloads. Specifically, in the case of pro-
grammable parameters, the system can transmit data on
diagnostic variables, arrhythmias, ICD therapies delivered
and battery/lead issues, and can alert the physician via
phone or e-mail.
The patient's information is sent to a secure Network
server via the telephone connection. The clinical staff can
review device information on a secure Website via the
Internet. Available data are equivalent to those which can
be retrieved at an in-office visit.
Hypothesis
It is hypothesized that patients implanted with ICD/CRT-
D devices endowed with the CareLink system will require
less attention for cardiac or device-related episodes than
patients whose devices do not have such features.
Objectives
The primary objective of the study is to determine whether
patients using the CareLink system display a different rate
of unplanned cardiac or device-related in-hospital visits
from patients in the standard arm. The endpoints for this
objective include all cardiac and device-related clinic vis-
its, i.e. all hospital admissions not involving an overnight
stay, when the interval between the decision to admit and
the admission is <24 hours. The events anticipated to
prompt these visits are: ICD alerts regarding system integ-
rity, atrial and ventricular arrhythmias, decrease in intra-
thoracic impedance signifying possible fluid accumula-
tion, and patients' symptoms. These endpoints will be
subdivided according to whether the visits are related or
not related to episodes of worsening of HF; estimation of
their respective rates will constitute a secondary objective
of the study.
Additionally, the rate and related costs of total healthcare
utilizations (all planned and unplanned hospital admis-
sions involving and not involving an overnight stay) for
cardiac or device-related events will be compared between
groups. For this objective, hospital visits will be also scru-
tinized and classified as necessary or unnecessary for the
clinical management of the patient. In particular, eachPage 2 of 11
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Trials 2009, 10:42 http://www.trialsjournal.com/content/10/1/42visit will be judged necessary if it results from an appropri-
ate and clinically meaningful ICD alert (e.g.: intra-tho-
racic impedance alert associated with clinically
deteriorated HF) and if the clinician was not previously
aware of the clinical/ICD condition.
Other variables
This study will also test whether the CareLink system:
• Reduces the time between the onset of asymptomatic
events and the clinical decision on such events;
• Modifies the degree of patient anxiety, as measured by
the composite scores of both the State and Trait compo-
nents of the State-Trait Anxiety Inventory – Form Y;
• Modifies the patient's clinical status, as measured by the
Clinical Composite Score [14];
• Modifies the patient's quality of life, as measured by the
Minnesota Living with Heart Failure Questionnaire and
the EQ-5D Questionnaire.
Design
This is a one-to-one randomized, prospective study. The
study has been approved by the Institutional Review
Board of the 6 participating Italian centers.
Patients implanted with wireless-transmission-enabled
Medtronic ICD or CRT-D will be randomized to "remote
transmission on" (remote arm) or "remote transmission
off" (standard arm) (Figure 1).
Trial designFigure 1
Trial design. Enrollment and follow-up schedule.Page 3 of 11
(page number not for citation purposes)
Trials 2009, 10:42 http://www.trialsjournal.com/content/10/1/42Randomization will be stratified by center and by time
from implantation (≤ 6 months and > 6 months) to min-
imize selection bias and preserve homogeneity between
arms with regard to stability of clinical status.
In the remote arm, devices will be programmed to trans-
mit over the CareLink Network. Devices in the standard
arm will have all features available in their ICD/CRT-D,
including the audible notification of alerts, but will not
have access to the CareLink Network.
Patient population
This study requires 200 patients that meet all inclusion
criteria.
Inclusion criteria
• Left ventricular systolic dysfunction, left ventricular ejec-
tion fraction ≤35%, as documented at the moment of ICD
implantation;
• Implantation with a wireless-transmission-enabled
Medtronic ICD or CRT-D;
• Ability and willingness to undergo remote follow-up
instead of scheduled routine in-office follow-up visits;
• Ability to attend all required follow-up examinations at
the study center.
Exclusion criteria
• Age less than 18 years;
• Unwillingness or inability to give informed consent;
• Life expectancy less than 12 months;
• Participation in another clinical study that may have an
impact on the endpoints of the present study.
Procedures
Patients previously implanted with the above-mentioned
devices will be brought in for a standard in-office exami-
nation and assessment of the inclusion criteria. After sign-
ing an informed consent form and being randomization
to either the remote or standard arm, patients will be fol-
lowed up for a 16-month period, with required visits after
4, 8, 12 months (only for standard arm) and 16 months.
In the remote arm CareLink transmissions will replace the
4- and 12-month visits (Figure 1).
Table 1 summarizes the data to be collected at the baseline
and during follow-up.
Device programming
Initial ICD programming is to be performed at the time of
randomization. Tables 2 and 3 show detailed lists of all
protocol-required device programming parameters.
In summary, all alerts regarding clinical management
(intra-thoracic impedance for fluid accumulation moni-
toring, atrial arrhythmias, ICD shocks delivered) will be
turned on for wireless notification through the CareLink
in the remote arm, while no audible alerts will be used. In
the standard arm these alerts will be turned on for audible
notification only.
All lead and device integrity alerts will be turned on for
both wireless and audible notification in the remote arm,
and for only audible notification in the standard arm.
In the standard arm, audible alerts for intra-thoracic
impedance monitoring will be programmed to sound at a
different time of the day from alerts for other causes, in
order to distinguish them.
Clinicians are allowed to turn off the alert for atrial
arrhythmias, if they are no longer attempting to control
the subject's atrial rhythm. Similarly, they can turn off the
alert for intra-thoracic impedance when recurrent inap-
propriate detections of fluid accumulation are docu-
mented.
Management strategies
Clinics will be allowed to restrict notification of alerts to
business hours, but will be encouraged to check the Care-
Link website at least once daily for transmissions.
If the clinic is notified of an audible alert sounding (both
arms) or an alert received via CareLink (remote arm only),
or if subjects report signs or symptoms, the clinician is
required to implement management strategies that
exploit the respective features available in the two arms. A
summary of management strategy requirements is listed
in Figure 2 for the standard arm, and in Figure 3 and 4 for
the remote arm.
Assessment of the patient's clinical status and verification
of appropriate functioning of the ICD will be performed
in accordance with the current guidelines and the center's
routine practice.
Statistical methods
An intention-to-treat analysis will be performed on all
randomized subjects and will serve as the primary analysis
for all objectives in this study.
The primary and secondary hypotheses will be tested by
using the Comparison of Incidence Rates (Large Sample)Page 4 of 11
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will be used.
Cost analysis will be carried out from the perspectives of
the healthcare system and the patient. Consequently, the
unit costs considered will be related to the public tariffs or
to the patient's out-of-pocket expenses. The in-hospital
resources related to the introduction and utilization of
CareLink will also be evaluated.
Sample size justification
The sample size requirements for this study are intended
to provide adequate power for the analysis of the primary
objective.
Simulation methods used data extrapolated from a popu-
lation of 160 CRT-D patients followed up for 224 ± 130
days (data on file). Overall, 220 episodes occurred over 98
person-years (2.2 per person-year):
• 140 intra-thoracic impedance alerts;
• 34 episodes of atrial arrhythmia >12 hours in a single
day;
• 6 additional episodes of atrial arrhythmia >6 hours with
ventricular rate >100 beats/min in a single day;
• 40 ICD shocks delivered.
The simulations were run in R Software 2.4.1 according to
the following hypotheses: the incidence density used as a
null hypothesis was 2.2 per person-year; this rate is
expected to decrease by 10% in the study arm; it was
assumed that 20% of patients would drop out uniformly
over the follow-up period; the target type-I error (α) was
0.05.
A sample size of 100 subjects per group would allow a
power of 99.8% (95% confidence interval: 96.0 – 100.0)
to detect an incidence rate ratio of 0.90, with a type-I error
of 0.05.
Table 1: Overview of data collection requirements





Healthcare Utilization X X * X X * X
Alerts X X X X X
Symptoms X X * X X * X
Echocardiographic parameters X X
NYHA Class X X * X X * X
Save-to-Disk ICD Data X X * X X * X
Patient Questionnaires
State Trait Anxiety Inventory X X X
MLHF X X
EQ-5D X X
Patient and Caregiver Burden X
* in Standard Arm onlyPage 5 of 11
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Rationale for objectives
The CareLink system performs full interrogation and
transmission of ICD data, and available information is no
different from that retrieved during an in-office visit. The
main advantage lies in the possibility of early reaction to
patient symptoms and device alerts without the patient
having to come to the hospital for either scheduled or
unscheduled examinations.
As suggested [10,15], adoption of the CareLink system
should enable cardiac or ICD-related episodes to be suc-
cessfully managed through remote data review and tele-
phone follow-up, without requiring additional in-
hospital visits. This will be ascertained by measuring the
reduction in the rate of unplanned in-hospital visits (pri-
mary objective). Moreover, it is hypothesized that this
reduction will concern both visits related to the worsening
of HF and those that are not HF-related, which in current
clinical practice are managed by the heart failure specialist
and the electrophysiologist, respectively. More generally,
it is supposed that the rate and the costs of total healthcare
utilizations for cardiac or ICD-related events will decrease;
this will be tested as a secondary objective.
Rationale for design
Currently, outpatient follow-up examinations of ICD
patients are scheduled at regular 3- to 6-month intervals
[8,9]. In the present study, we will compare a standard
arm undergoing 4 in-office examinations per year with a
remote arm in which 2 of the 4 examinations are replaced
by remote interrogations, as previously proposed [16,17].
Table 2: Alert programming. Clinical Management Alerts
Remote Arm Standard Arm
Intra-thoracic Impedance Monitoring (OptiVol Alert)
OptiVol Alert – Device Off On
OptiVol Alert – Monitor On Off
AT/AF Burden and Rate Settings
AT/AF Daily Burden Alert Enable – Device * Off On
AT/AF Daily Burden Alert Enable – Monitor * On Off
- Daily AT/AF Alert Burden 6 hours 6 hours
Avg. V. Rate During AT/AF Alert Enable – Device ** Off On
Avg. V. Rate During AT/AF Alert Enable – Monitor ** On Off
- Avg. V. Rate During AT/AF 100 beats/min 100 beats/min
- Daily Burden for Avg. V. Rate 6 hours 6 hours
Number of Shocks Delivered during an Episode
Alert Enable – Device Off Off
Alert Enable – Monitor On Off
- Threshold Number of Shocks 1 -
All Therapies in a Zone Exhausted for an Episode
Alert Enable – Device Off On
Alert Enable – Monitor On Off
* To pursue a "Rhythm Control" strategy; ** To pursue a "Rate Control" strategyPage 6 of 11
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usually prompt the subject to seek urgent attention at the
clinic, will be managed via CareLink and telephone fol-
low-up in the remote arm. Indeed, it has been recently
shown that a considerable portion of post-shock interro-
gations do not involve reprogramming of the ICD and
may therefore be performed remotely [10,15].
The audible alert feature has been shown to facilitate the
early discovery of serious ICD complications [7], and
improved alert algorithms have recently been imple-
mented to detect lead failures promptly [6]. Similarly, in
view of the high incidence of atrial fibrillation in HF [18]
and the consequent increased risk of decompensation,
stroke and inappropriate shocks, the advanced ICD capa-
bilities for detecting atrial arrhythmias have the potential
to play a growing role in patient monitoring [5]. By pro-
viding remote notification and access to details of the
occurrence and duration of atrial fibrillation and ventricu-
lar response, CareLink will facilitate the management of
therapies for rhythm or rate control and the prompt
administration of anticoagulants for stroke prevention.
Continuous intra-thoracic impedance monitoring in
modern ICD is intended to detect HF decompensation
promptly, thereby permitting early therapeutic interven-
tion [4]. Decreased intra-thoracic impedance has been
shown to reliably identify acute HF, with low rates of
undetected events [19], and to be associated with an
increased risk of HF hospitalization [20]. As recently
shown [15], a high percentage of episodes may be success-
fully and promptly managed through CareLink without
requiring additional in-hospital visits, by means of
remote data review and assessment of symptom status
and therapy compliance by phone. Moreover, patients
might not hear or respond to the audible impedance alert,
as recently reported [21]. Thus, automated telemetric
transmission of alerts to the physician may shorten the
delay between alert and therapy initiation, further
improving the clinical outcome.
Other trials have used a control arm blinded to device
data [22], in order to test the clinical value of diagnostic
features. By contrast, in the present study all alerts will be
turned on for audible notification in the standard arm and
the diagnostics will be open for in-office review. This will
enable the benefits associated to remote notification and
Table 3: Alert programming. Lead/Device Integrity Alerts
Remote Arm Standard Arm
Patient Home Monitor On Off
Lead Impedance Out of Range
(A. pacing, LV pacing*, RV pacing, RV defibrillation, SVC defibrillation**)
Alert Enable – Device On-High On-High
Alert Enable – Monitor On Off
Low Battery Voltage RRT
Alert Enable – Device On-High On-High
Alert Enable – Monitor On Off
Excessive Charge Time EOS
Alert Enable – Device On-High On-High
Alert Enable – Monitor On Off
VF Detection/Therapy Off
Alert Enable – Device On-High On-High
Alert Enable – Monitor On Off
* For systems with an LV lead; ** For systems with dual-coil leadsPage 7 of 11
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to the diagnostic and alerting capabilities of modern ICD.
Another trial is currently investigating the CareLink sys-
tem in pacemaker patients [23]. The present study on
ICD/CRT-D patients, however, will focus on a sicker pop-
ulation with more complex devices. This is the setting in
which remote monitoring is presumed to offer the greatest
benefits.
In the hypothesis of a more stable clinical status of the
patient and a reduced need to adjust ICD parameters 6
months after implantation [10], stratifying patient rand-
omization on the basis of time since implantation will
limit a potential bias.
Summary
Through a retrospective analysis of device-stored data
from patients implanted with CRT-D [10], we recently
assessed the potential impact of remote follow-up in clin-
ical practice and demonstrated that it can constitute a
practical alternative to frequent scheduled and unsched-
uled in-office visits.
Subsequently, in the framework of the multicenter Italian
CareLink evaluation, we showed that the ease of use, sat-
isfaction and acceptance of the system in European clini-
Management strategy requirementsFigur  2
Management strategy requirements. Operative flowcharts for the management of device shocks and alerts in the stand-
ard arm.Page 8 of 11
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Trials 2009, 10:42 http://www.trialsjournal.com/content/10/1/42cal practice is high among both patients and clinicians
[17]. We therefore suggested that, by improving the clini-
cal management of tachyarrhythmias and HF episodes in
CRT-D patients, this system may lead to a reduction in
healthcare utilizations, if included in a disease manage-
ment program [15]. This hypothesis is to be tested in the
present randomized controlled study, which has been
designed to compare the remote management of ICD/
CRT-D patients with the current standard of care.
Patient enrollment began in May 2008 and is projected to
end by May 2009. Follow-up will be for 16 months after
the last enrollment and is expected to end in September
2010.
Abbreviations
CRT-D: defibrillators for resynchronization therapy; ED:
emergency department; ICD: implantable defibrillator.
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